Table 3.
Univariable and multivariable models evaluating initial adherence with guideline-concordant active surveillance monitoring protocola n= 2067 (multivariable).
| Variable | Level | Univariable hazard ratio (95% CI) |
p value | Multivariable hazard ratio (95% CI) |
p value |
|---|---|---|---|---|---|
| Age | <77 77+ |
Reference 0.48 (0.42, 0.55) |
<0.01 | Reference 0.45 (0.39, 0.52) |
<0.01 |
| Race | White Black Other |
Reference 0.50 (0.36, 0.70) 0.81 (0.62, 1.06) |
<0.01 | Reference 0.58 (0.38, 0.87) 0.79 (0.59, 1.06) |
<0.01 |
| Ethnicity | Non-Hispanic Hispanic |
Reference 0.80 (0.50, 1.27) |
0.34 | - | - |
| Married/partner | Yes No |
Reference 0.69 (0.54, 0.88) |
<0.01 | Reference 0.75 (0.59, 0.96) |
0.02 |
| Income (ZIP code median) | <$40,000 $40–60,000 >$60,000 |
Reference 1.41 (1.15, 1.74) 1.97 (1.68, 2.31) |
<0.01 | Reference 1.47 (1.15, 1.86) 2.04 (1.71, 2.44) |
<0.01 |
| Comorbidity | 2+ 0 1 |
Reference 1.44 (1.04, 2.00) 1.33 (1.03, 1.72) |
0.08 | Reference 1.18 (0.87, 1.59) 1.26 (0.99, 1.62) |
0.08 |
| PSA (ng/mL) | 4–9.9 <4 |
Reference 1.21 (1.13, 1.29) |
<0.01 | Reference 1.11 (1.03, 1.20) |
<0.01 |
| Derived AJCC T stage | T2a T1c |
Reference 0.99 (0.63, 1.55) |
0.97 | - | - |
| Year of diagnosis | 2010 2011 2012 2013 |
Reference 0.94 (0.75, 1.17) 1.01 (0.87, 1.18) 1.14 (1.04, 1.24) |
0.03 | Reference 0.98 (0.81, 1.17) 0.98 (0.85, 1.13) 1.12 (1.00, 1.26) |
0.22 |
a
≥ one biopsy and ≥ two PSA tests within 24 months of diagnosis.